Taysha Gene Therapies Prices $195M Public Offering at $6 Per Share
TSHA has more than doubled off its 52-week low of $2.25.
Summary
Taysha Gene Therapies has priced its public offering, selling 32.5 million shares of common stock and pre-funded warrants at $6 each, raising $195 million. This follows yesterday's announcement of a proposed $200 million offering. The capital infusion is substantial, representing nearly 10% of the company's market capitalization, and will significantly bolster its financial position. This funding is critical for advancing its gene therapy pipeline, including the recently completed dosing in the pivotal REVEAL trial for TSHA-102.
At the time of this announcement, TSHA was trading at $6.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.25 to $7.30. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.